(AOF) – Global Bioenergies announces a net loss of 8.65 million euros in 2023, compared to nearly 12 million in 2022. This company, which replaces products of petroleum origin with products of natural origin, emphasizes that its cash flow of 11.7 million euros as of December 31 ensures its financial visibility for the entire 2024 financial year. The turnover crossed the 3 million euros mark for the first time, at 3 .24 million compared to 698,000 euros in 2022.
The group has delivered its first orders for several tonnes of Isonaturane 12.
“This performance reflects the major progress made by the group in 2023,” comments Samuel Dubruque, administrative and financial director of Global Bioenergies. “On the cosmetic side, we were able to meet the expectations of our customers by delivering our first commercial batches. On the air side, ASTM certification propels our innovation into the very restricted circle of technologies that can be used in all airliners on a scale international.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.